ReCode Therapeutics
1455 Adams Drive, Suite 1120
Menlo Park, CA 94025
United States
Tel: 408-585-1700
Website: https://recodetx.com/
Email: info@recodetx.com
About ReCode Therapeutics
We are an integrated genetic medicines company developing targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. Our treatments address the underlying genetic cause in underserved populations and have the potential to tremendously impact the quality and length of patients’ lives. We have created a broad and customizable platform of non-viral lipid nanoparticles (LNPs), enabling us to precisely deliver our medicines safely and effectively.
With our SORT LNP delivery platform, we can hone in on previously inaccessible targets by delivering the payload precisely to a specific organ. Our proprietary delivery platforms can be customized to treat different respiratory diseases and targeted organs. Our ability to carry different types of cargo (mRNA, tRNA, CRISPR) with multiple delivery systems allows us to advance several drug candidates simultaneously. Ultimately, we match the best delivery approach to the specific problem, providing incredible flexibility in how we can potentially treat patients.
By harnessing our deep experience with well-defined drug development and regulatory pathways, we will rapidly advance our lead programs for cystic fibrosis (CF) caused by nonsense mutations and primary ciliary dyskinesia (PCD) – ultimately having a significant effect where there is a clear, unmet, and high-hurdle need.
30 articles with ReCode Therapeutics
-
ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference
5/15/2022
ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery presented new preclinical data from the company’s inhaled mRNA-based molecular therapy program for the treatment of primary ciliary dyskinesia in three posters at the American Thoracic Society 2022 International Conference, taking place May 13-18, 2022 in San Francisco.
-
ReCode Therapeutics to Present at 2022 RBC Capital Markets Global Healthcare Conference
5/10/2022
ReCode Therapeutics , a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat on Tuesday, May 17th from 2:05 - 2:30 p.m. ET.
-
ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform From Its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco
5/3/2022
ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting (SORT) lipid nanoparticles (LNP) delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic programs in cystic fibrosis and primary ciliary dyskinesia at the American Thoracic Society’s ATS 2022 International Conference.
-
ReCode Therapeutics to Present at Oppenheimer 32nd Annual Healthcare Conference
3/9/2022
ReCode Therapeutics announced that Shehnaaz Suliman, M.D., MBA, M.Phil, chief executive officer of ReCode Therapeutics will present a corporate overview at the upcoming Oppenheimer 32nd Annual Healthcare Conference being held virtually from March 15-16, 2022.
-
Suliman anticipates filing an Investigational New Drug application with the FDA for the PCD asset this year, and next year filing one for the cystic fibrosis asset.
-
ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
1/10/2022
ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference.
-
ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer
1/10/2022
ReCode Therapeutics today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today.
-
ReCode Therapeutics to Participate in Upcoming November Investor Conferences
11/8/2021
ReCode Therapeutics today announced that Company leadership will participate in two upcoming virtual investor conferences in November: 2021 Stifel Healthcare Conference Format: Live Presentation Date: Monday, November 15, 2021 Time: 4:40 p.m.
-
ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference
11/3/2021
ReCode Therapeutics presented new preclinical data today from the Company’s inhaled mRNA-based therapeutic program for cystic fibrosis (CF) during an oral poster session at the 2021 North American Cystic Fibrosis Conference (NACFC).
-
Money on the Move: October 20 – 26
10/27/2021
While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks. -
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
10/21/2021
ReCode Therapeutics today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
-
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
-
ReCode Therapeutics to Present Preclinical Data from mRNA-based Program for Cystic Fibrosis at Upcoming Virtual 2021 North American Cystic Fibrosis Conference
10/19/2021
ReCode Therapeutics today announced that it will present preclinical data from its mRNA-based therapeutic program for cystic fibrosis (CF) in a poster presentation at the upcoming 2021 North American Cystic Fibrosis Conference (NACFC) to be held virtually from November 2-5, 2021.
-
ReCode Therapeutics Announces Participation in Upcoming October Investor Conferences
9/28/2021
ReCode Therapeutics today announced that Company leadership will participate in three upcoming virtual investor conferences in October: Chardan 5th Annual Genetic Medicines Conference Format: Presentation Date: Monday, October 4, 2021
-
ReCode Therapeutics Appoints Nicholas P. France, M.D., as Senior Vice President of Clinical Development
9/27/2021
ReCode Therapeutics today announced the appointment of Nicholas P. France, M.D., MRCPCH, as senior vice president, clinical development.
-
ReCode Therapeutics Announces Participation in Upcoming Investor Conferences
9/3/2021
ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences.
-
ReCode Therapeutics Appoints Angèle Maki, Ph.D., as Senior Vice President of Business Development
8/16/2021
ReCode Therapeutics today announced the appointment of Angèle Maki, Ph.D., as senior vice president, business development.
-
ReCode Therapeutics Presents Encouraging Preclinical Data from Inhaled mRNA Therapeutics Program in Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference
8/5/2021
ReCode Therapeutics today presented encouraging preclinical data from the Company’s inhaled mRNA-based molecular therapy program for the treatment of primary ciliary dyskinesia (PCD) during an oral and poster session at the 2021 PCD on the Move Virtual Scientific Conference.
-
ReCode Therapeutics to Participate in Upcoming August Investor Conferences
8/3/2021
ReCode Therapeutics today announced that Company leadership will host 1x1 meetings at two upcoming virtual investor conferences in August: Canaccord Genuity 41 st Annual Growth Conference. Dates: August 10 – 12, 2021
-
ReCode Therapeutics to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference
7/30/2021
ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced preclinical data from the Company’s inhaled mRNA-based molecular therapy program for primary ciliary dyskinesia will be presented in an oral and poster presentation at the 2021 PCD on the Move Virtual Scientific Conference,